Skip to main content
. Author manuscript; available in PMC: 2021 Aug 6.
Published in final edited form as: Mol Cancer Ther. 2019 May 29;18(8):1439–1450. doi: 10.1158/1535-7163.MCT-18-0833

Figure 4. The BRD4 inhibitor AZD5153 suppresses cell migration via targeting Mus81 in gastric cancer cells.

Figure 4.

(A) Heat map of Mus81 expression levels in SGC7901 cells treated with the indicated drugs for 24 h. Data are presented for three independent experiments. (B and C) qPCR (B) and western blot (C) analyses of Mus81 and ZEB1 expression levels in SGC7901 and BGC823 cells treated with indicated concentrations of AZD5153 (one-way ANOVA). (D) Cell migration analysis using Transwell assays in SGC7901 and BGC823 treated with AZD5153 at the indicated concentration for 24 hours. Data are reported as the mean ± SD of three independent experiments (one-way ANOVA). (E and F) qPCR and western blot analyses of Mus81 and ZEB1 expression levels in SGC7901 and BGC823 cells after transfected with BRD4 siRNAs (G) Cell migration analysis using Transwell assays in BRD4 knockdown SGC7901 and BGC823 cells. Data are reported as the mean ± SD of three independent experiments (t test). (H) Western blot showed Mus81 expression in Mus81-depleted BGC823 cells treated with AZD5153 at the indicated concentration. (I) Cell migration analysis using Transwell assays in Mus81-depleted BGC823 cells treated with AZD5153 at indicated the concentration. Data are reported as the mean ± SD of three independent experiments. *, P < 0.05; **, P < 0.01; ns., not significant.